Hemorrhagic Cystitis (BK Virus)
Overview
Plain-Language Overview
Hemorrhagic cystitis (BK virus) is a condition where the bladder becomes inflamed and bleeds, causing blood in the urine. It mainly affects the urinary system, specifically the bladder lining. This condition often occurs in people with weakened immune systems, such as those who have had a bone marrow or kidney transplant. The main symptoms include painful urination, frequent urination, and visible blood in the urine. The bleeding results from damage to the bladder caused by the BK virus, which is a common virus that can reactivate in these patients. This condition can lead to discomfort and complications if not properly managed.
Clinical Definition
Hemorrhagic cystitis (BK virus) is an inflammatory condition of the bladder characterized by mucosal hemorrhage and epithelial damage caused by reactivation of latent BK polyomavirus in immunocompromised hosts. It most commonly occurs in patients undergoing hematopoietic stem cell transplantation or solid organ transplantation due to immunosuppression. The virus infects urothelial cells, leading to cytopathic effects, inflammation, and bleeding. Clinically, it presents with gross hematuria, dysuria, and urinary frequency. The condition is significant because it can cause severe bleeding, urinary obstruction, and prolonged hospitalization. Diagnosis and management are critical to prevent complications such as bladder fibrosis or renal impairment.
Inciting Event
Immunosuppressive conditioning regimens prior to HSCT trigger BK virus reactivation.
Urothelial injury from chemotherapy or radiation facilitates viral replication and mucosal damage.
Engraftment and immune reconstitution phases can modulate viral activity and symptom onset.
Latency Period
Symptoms typically develop 2 to 8 weeks post-transplantation during the period of maximal immunosuppression.
BK virus remains latent for months to years before reactivation under immunosuppressive conditions.
Diagnostic Delay
Hematuria is often initially attributed to chemotherapy toxicity or bacterial urinary tract infection.
Lack of early suspicion for BK virus leads to delayed urine PCR or cytology testing.
Overlap with graft-versus-host disease symptoms can obscure diagnosis.
Clinical Presentation
Signs & Symptoms
Gross hematuria often with clots is the hallmark symptom.
Dysuria and urinary frequency due to bladder mucosal irritation.
Lower abdominal pain or suprapubic discomfort is common.
Fever may accompany viral reactivation or secondary bacterial infection.
Urinary retention can occur in severe cases due to clot obstruction.
History of Present Illness
Patients present with gross hematuria, often accompanied by dysuria and urinary frequency.
Symptoms progress from mild irritative voiding to severe hemorrhagic cystitis with clot retention.
Onset is typically subacute, developing over days to weeks after transplantation.
Past Medical History
History of allogeneic HSCT with recent conditioning chemotherapy is critical.
Prior immunosuppressive therapy including corticosteroids or calcineurin inhibitors increases risk.
Previous BK virus infection or seropositivity indicates latent virus reservoir.
Family History
There are no known hereditary or familial syndromes associated with BK virus hemorrhagic cystitis.
Family history is generally not contributory to disease risk or presentation.
Physical Exam Findings
Suprapubic tenderness on palpation indicating bladder inflammation.
Gross hematuria visible during external genital examination.
Bladder distension may be noted if urinary retention occurs.
Fever may be present if concurrent infection or systemic inflammation occurs.
Diagnostic Workup
Diagnostic Criteria
Diagnosis of hemorrhagic cystitis due to BK virus is established by the presence of gross hematuria and urinary symptoms in an immunocompromised patient, especially post-transplant. Confirmation requires detection of BK virus DNA in the urine or plasma by polymerase chain reaction (PCR). Cystoscopy may reveal bladder mucosal hemorrhage and inflammation. Urine cytology can show decoy cells indicative of BK virus infection. Exclusion of other causes of hemorrhagic cystitis, such as bacterial infection or chemotherapy toxicity, is essential.
Pathophysiology
Key Mechanisms
Reactivation of latent BK virus in urothelial cells causes direct cytopathic damage to the bladder mucosa.
Immune suppression after transplantation impairs viral clearance, allowing viral replication and tissue injury.
Inflammation and hemorrhage result from viral-induced urothelial cell lysis and local immune response.
Endothelial damage in bladder vasculature contributes to bleeding and hemorrhagic cystitis.
| Involvement | Details |
|---|---|
| Organs | Urinary bladder is the organ affected by BK virus causing hemorrhagic cystitis with hematuria and dysuria. |
| Tissues | Bladder mucosa is the site of viral cytopathic effect and hemorrhage leading to cystitis symptoms. |
| Cells | Urothelial cells are the primary target of BK virus infection causing cytopathic damage and hemorrhagic cystitis. |
T lymphocytes mediate immune response controlling viral replication and inflammation in the bladder mucosa. | |
| Chemical Mediators | Interleukin-6 (IL-6) is elevated in the bladder during inflammation and contributes to local immune activation. |
Tumor necrosis factor-alpha (TNF-α) promotes urothelial injury and inflammatory response in hemorrhagic cystitis. |
Treatments
Pharmacological Treatments
Cidofovir
- Mechanism:
Inhibits viral DNA polymerase, reducing BK virus replication.
- Side effects:
Nephrotoxicity
Neutropenia
Electrolyte imbalances
- Clinical role:
Second-line
Intravenous Immunoglobulin (IVIG)
- Mechanism:
Provides passive immunity and modulates immune response against BK virus.
- Side effects:
Infusion reactions
Thrombosis
Renal dysfunction
- Clinical role:
Adjunctive
Non-pharmacological Treatments
Maintain adequate hydration to flush the urinary tract and reduce hemorrhagic cystitis symptoms.
Continuous bladder irrigation to prevent clot formation and relieve urinary obstruction.
Reduce or discontinue immunosuppressive therapy when possible to enhance immune control of BK virus.
Prevention
Pharmacological Prevention
Reduction of immunosuppressive therapy to prevent BK virus reactivation.
Cidofovir has been used off-label for BK virus prophylaxis in high-risk patients.
Leflunomide may have antiviral activity against BK virus in transplant recipients.
Non-pharmacological Prevention
Regular BK virus screening by PCR in urine or blood for early detection post-transplant.
Adequate hydration to reduce urinary stasis and mucosal irritation.
Minimizing immunosuppressive drug doses to the lowest effective level.
Prompt management of urinary tract infections to prevent exacerbation.
Outcome & Complications
Complications
Urinary tract obstruction from blood clots causing acute retention.
Secondary bacterial urinary tract infection due to mucosal damage.
Chronic bladder fibrosis leading to reduced bladder capacity and compliance.
Renal dysfunction from obstructive uropathy or BK virus nephropathy.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Hemorrhagic Cystitis (BK Virus) versus Cyclophosphamide-induced Hemorrhagic Cystitis
Hemorrhagic Cystitis (BK Virus) | Cyclophosphamide-induced Hemorrhagic Cystitis |
|---|---|
History of immunosuppression or bone marrow transplant with BK virus reactivation | Recent or ongoing treatment with cyclophosphamide or ifosfamide chemotherapy |
Urine PCR positive for BK virus DNA | Urine positive for acrolein metabolites and negative for BK virus DNA |
Hemorrhagic cystitis develops weeks to months after transplant due to viral reactivation | Hemorrhagic cystitis typically occurs during or shortly after chemotherapy |
Hemorrhagic Cystitis (BK Virus) versus Adenovirus-associated Hemorrhagic Cystitis
Hemorrhagic Cystitis (BK Virus) | Adenovirus-associated Hemorrhagic Cystitis |
|---|---|
Detection of BK virus DNA in urine or blood | Detection of adenovirus DNA in urine or blood |
Occurs in both pediatric and adult transplant recipients | More common in pediatric transplant recipients |
Positive BK virus PCR from urine or plasma | Positive adenovirus PCR or culture from urine |
Hemorrhagic Cystitis (BK Virus) versus Radiation-induced Hemorrhagic Cystitis
Hemorrhagic Cystitis (BK Virus) | Radiation-induced Hemorrhagic Cystitis |
|---|---|
No history of radiation; history of immunosuppression or transplant | History of pelvic radiation therapy |
Symptoms develop weeks to months after transplant | Symptoms develop months to years after radiation exposure |
Bladder biopsy shows viral cytopathic changes with BK virus inclusions | Bladder biopsy shows fibrosis, endarteritis, and telangiectasia without viral inclusions |
Hemorrhagic Cystitis (BK Virus) versus Bacterial Urinary Tract Infection with Hematuria
Hemorrhagic Cystitis (BK Virus) | Bacterial Urinary Tract Infection with Hematuria |
|---|---|
Urine culture negative; PCR positive for BK virus | Urine culture positive for bacterial pathogens such as Escherichia coli |
Urinalysis shows hematuria with minimal pyuria | Urinalysis shows pyuria and bacteriuria |
No improvement with antibiotics; requires antiviral or supportive care | Improvement with antibiotic therapy |
Hemorrhagic Cystitis (BK Virus) versus Schistosomiasis-associated Hemorrhagic Cystitis
Hemorrhagic Cystitis (BK Virus) | Schistosomiasis-associated Hemorrhagic Cystitis |
|---|---|
No travel or exposure history; associated with immunosuppression | History of exposure to freshwater in endemic areas (Africa, Middle East) |
Bladder biopsy shows viral inclusions consistent with BK virus | Bladder biopsy shows Schistosoma haematobium eggs with granulomatous inflammation |
Detection of BK virus DNA by PCR in urine | Detection of Schistosoma eggs in urine |